JPMorgan Weighs in on Eli Lilly's (LLY) Upcoming Donanemab Data

March 2, 2021 6:24 AM EST Send to a Friend
JPMorgan analyst Chris Schott reiterated an Overweight rating and $240.00 price target on Eli Lilly (NYSE: LLY) as investors approach ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login